- Home
- ORKT vs AGEN Comparison
ORKT vs AGEN Comparison
Compare ORKT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKT
- AGEN
- Stock Information
- Founded
- ORKT 2003
- AGEN 1994
- Country
- ORKT Singapore
- AGEN United States
- Employees
- ORKT N/A
- AGEN N/A
- Industry
- ORKT
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ORKT
- AGEN Health Care
- Exchange
- ORKT NYSE
- AGEN Nasdaq
- Market Cap
- ORKT 82.9M
- AGEN 96.2M
- IPO Year
- ORKT 2024
- AGEN 2000
- Fundamental
- Price
- ORKT $3.07
- AGEN $2.84
- Analyst Decision
- ORKT
- AGEN Buy
- Analyst Count
- ORKT 0
- AGEN 3
- Target Price
- ORKT N/A
- AGEN $9.33
- AVG Volume (30 Days)
- ORKT 2.7M
- AGEN 478.9K
- Earning Date
- ORKT 11-19-2024
- AGEN 11-12-2024
- Dividend Yield
- ORKT N/A
- AGEN N/A
- EPS Growth
- ORKT N/A
- AGEN N/A
- EPS
- ORKT N/A
- AGEN N/A
- Revenue
- ORKT $3,904,592.00
- AGEN $160,427,000.00
- Revenue This Year
- ORKT N/A
- AGEN N/A
- Revenue Next Year
- ORKT N/A
- AGEN $0.04
- P/E Ratio
- ORKT N/A
- AGEN N/A
- Revenue Growth
- ORKT N/A
- AGEN 59.00
- 52 Week Low
- ORKT $1.45
- AGEN $2.74
- 52 Week High
- ORKT $8.00
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- ORKT N/A
- AGEN 20.16
- Support Level
- ORKT N/A
- AGEN $2.98
- Resistance Level
- ORKT N/A
- AGEN $4.42
- Average True Range (ATR)
- ORKT 0.00
- AGEN 0.26
- MACD
- ORKT 0.00
- AGEN -0.10
- Stochastic Oscillator
- ORKT 0.00
- AGEN 1.87
About ORKT ORANGEKLOUD TECHNOLOGY INC
Orangekloud Technology Inc is a company that operates through its subsidiaries provide IT consultancy services and distribution of related products and services. The Company also offers ERPs predominately in Singapore. It derives revenue from platform subscriptions, license and products and professional services.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).